Skip to content


REsearch summary

VIC seeks to accelerate the efficient & effective early-stage development of new vaccines & immunotherapies for infectious disease.

VIC has been successful in developing novel candidate vaccines and adjuvants for emerging infectious diseases and exploring intriguing aspects of their immunopathogenesis.

To this end current research priorities include:

Infectious Disease Pipeline

1 : Initial R&D

2 : Preclinical Efficacy

3 : Preclinical Safety

4 : Initial Human Studies

The Team at VIC rapidly pivoted during a couple of crucial weeks in March 2020 to address clear unmet medical needs for new diagnostics, treatments and a vaccine for SARS-CoV-2. Most importantly, we leveraged our ongoing Department of Defense funded rapid vaccine development platform, VaxCelerate, to target the coronavirus. To this end we partnered with a new biotechnology company, Voltron Therapeutics Inc., to take our new COVID-19 vaccine, called HaloVax, from bench to bedside on an accelerated timeline.

Highlighted Publications

Front Immunol. 2019 Feb 15;10:207. doi: 10.3389/fimmu.2019.00207. eCollection 2019. PMID: 30828331
Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC.

FASEB J. 2019 Feb;33(2):3074-3081. doi: 10.1096/fj.201801095R. Epub 2018 Sep 7. PMID:30192655
Gelfand JA, Nazarian RM, Kashiwagi S, Brauns T, Martin B, Kimizuka Y, Korek S, Botvinick E, Elkins K, Thomas L, Locascio J, Parry B, Kelly KM, Poznansky MC.

explore these labs for more info